Theromics

Theromics is a medical device company, spun out of Brown University in 2016, that is developing thermal accelerant technology to improve soft tissue ablation procedures. The company's co-founders are Dr. Damian Dupuy, who serves as Chief Medical Officer, and Dr. William K.C. Park, the Chief Scientific Officer. Their collaboration at Rhode Island Hospital led to the creation of the company's core technology. The current CEO is Dr. Suman Lal, who was appointed in January 2025.

The company's main products are HeatSYNC™ and CryoSYNC™, proprietary injectable nanogels made from a naturally occurring protein. These biocompatible nano-polymers are designed to enhance the transfer of energy in tissue, which allows for more focused and precise ablations. HeatSYNC™ works by amplifying heat energy, aiming to create larger ablation volumes in less time, while CryoSYNC™ enhances cryoablation by accelerating the freezing process to lethal temperatures for abnormal tissue. These gels are compatible with existing ablation technologies such as microwave, radiofrequency (RF), and cryoablation, and can be delivered via syringe, laparoscope, or bronchoscope. The technology aims to address the high recurrence rate of localized lesions (up to 30%) by overcoming limitations like incomplete ablation and insufficient energy penetration.

Theromics' business model focuses on selling its thermal accelerant products in partnership with manufacturers of ablation systems and probes who have established sales and distribution networks. The initial market focus is on tumor ablations, with plans to expand into other applications such as pain management and the treatment of uterine fibroids. Longer-term, the company intends to use its thermal technology as a platform for delivering oncolytic drugs and immunotherapies directly into tumors. As the products are for investigational use, they have not yet been cleared by the FDA. The company is preparing for its next FDA submission and aims to enter the market in 2025.

Keywords: thermal accelerant, nanogel, soft tissue ablation, medical device, interventional radiology, HeatSYNC, CryoSYNC, tumor ablation, immunotherapy delivery, cryoablation, microwave ablation, radiofrequency ablation, image-guided therapy, nanopolymer, protein-based, injectable gel, uterine fibroids, targeted drug delivery, energy-based therapy, thermal therapy